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Metastatic Disease With Laser
Interstitial Thermal Therapy
Afshin Salehi, Ashwin A. Kamath, Eric C. Leuthardt and Albert H. Kim*
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, United States
Treatment approaches for metastatic brain tumors continue to evolve, with increasing
recent emphasis on focal therapies whenever possible. MRI-guided Laser Interstitial
Thermal Therapy (LITT) is a minimally invasive surgical option that has broadened
the capability of the neurosurgeon in treating difficult-to-treat intracranial lesions. This
technology uses image-guided delivery of laser to the target lesion to generate heat and
thereby ablate pathological tissue and has expanded the neurosurgical armamentarium
for surgical treatment of brain metastases. In this study, we describe the indications for
LITT in the management of intracranial metastatic disease and report our institutional
experience with LITT.
Keywords: laser interstitial thermal therapy (LITT), intracranial metastatic disease, brain metastases, overall
survival (OS), thermal-damage-threshold (TDT)
INTRODUCTION
Current strategies for the treatment of metastatic brain tumors include surgical resection or
ablation, stereotactic radiosurgery, fractionated radiation therapy, whole brain radiation therapy
(WBRT), and in select cases, targeted medical therapy. Recent data indicate that rather than
performing WBRT, more focused and localized treatment of brain metastases using stereotactic
radiosurgery (SRS) might be favorable due to cognitive issues associated with WBRT (1). These
results also raise the general concept that focal therapies, where possible, should be preferentially
considered for brain metastases. Additionally, due to advances in the treatment of systemic disease
in this diverse group of patients, practitioners are encountering a growing number of patients with
brain metastases (2) and particularly patients who fail first- and even second-line therapy for their
intracranial disease.
Laser Interstitial Thermal Therapy (LITT) is a novel, highly focused, minimally invasive
technique that can be used to treat a variety of solid organ tumors (3, 4). The development of
complementary technologies, such as intraoperative magnetic resonance imaging (MRI) and real-
time MRI thermometry has enabled LITT to enter the fields of neurosurgery and neuro-oncology
(5–10). In recent years, LITT has been applied to intracranial lesions, including metastatic disease
to the brain, and has yielded safe and satisfactory treatment results with significantly less morbidity
(11) and shorter hospital stays than traditional open craniotomy (7).
Proper patient selection for the appropriate indication is of utmost importance in ensuring
the success of LITT. Firstly, patients must be willing to undergo a surgical procedure and be
able to medically tolerate general anesthesia. In general, the indications fall into the broad
categories of LITT as salvage therapy or frontline therapy. LITT has been used as frontline
therapy in surgically inaccessible tumors (12), such as thalamic or basal ganglia gliomas.
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Other work has shown LITT to be effective in managing
metastases that fail radiosurgery (13, 14) and in radiation
necrosis (13, 15). Conveniently, in cases where the diagnosis is
uncertain or would affect subsequent management, LITT can be
performed subsequent to stereotactic needle biopsy during the
same procedure.
LITT uses an MRI-compatible optical probe that transmits
laser light through to a sapphire tip. The probe is inserted into
the brain lesion with stereotactic guidance via a stab incision and
a simple burr hole. The laser then produces a controlled thermal
injury to the surrounding tissues. MRI thermometry allows for
continuous monitoring of ablation in a controlled manner. The
LITT procedure is generally well-tolerated with low operative
morbidity (11), which is especially desirable in the treatment of
cancer patients who often have significant systemic burden of
disease. LITT therefore offers a promising treatment modality
for intracranial metastatic disease. In this study, we describe our




Institutional review board approval was obtained for this research
(IRB #201609152). A retrospective database of LITT patients was
maintained and included demographics, age, sex, indications for
LITT, lesion type/location/dimensions as well as operative data,
such as procedure time, number of trajectories, post-operative
complications and readmission rates. Patients were followed
post-operatively. Overall survival was determined as time from
surgery until the time of death or time of last visit. PFS was
measured from the time of surgery until evidence of tumor
progression, time of last stable image, or death.
Operative Technique
The LITT procedure at our institution has previously been
described in detail (8, 9). In brief, for all procedures, Stealth
navigation (Medtronic Inc., Minneapolis, MN, USA) was used
for stereotaxy and trajectory planning. A registration error of
less than 2mm was used as a general goal. Intra-operative MRI
(IMRIS Inc, Minnetonka, MN, USA) was used for real-time MRI
thermography of the treatment zone. The planned trajectory was
evaluated in detail to avoid sulci and blood vessels, and generally,
the trajectory chosen was in line with the long axis of the lesion.
All patients received advanced MR imaging, including diffusion
tensor imaging (DTI), which was used to avoid passage through
eloquent white matter. Earlier in our series, we tended to use
the Monteris Axiis R© frame while later in the series, most cases
were performed with the Monteris R© Mini-Bolt as the laser base,
which has a low profile (142mm with driver). Yet in instances
with superficial lesions, the Axiis R© frame is advantageous due to
less artifact superficially in the cranium compared to the Mini-
Bolt. Typically, the stereotactic trajectory was aligned using the
Vertek R© arm (Medtronic Inc). A handheld Stryker drill was used
to generate a 4.5mm burr hole, through which the Monteris R©
bolt was screwed into the skull. Either diffusion tip or a side-fire
tip was inserted stereotactically into the tumor. Next, the intra-
operative MRI was brought into the operative theater, and initial
imaging obtained to confirm probe placement. The surgeon
then delivered laser therapy to the lesion while monitoring real-
time thermography via MRI to achieve appropriate heat dose
delivery. Post-operatively, patients were treated with Keppra and
a 2-to-3-weeks taper of dexamethasone.
Statistics
The Kaplan-Meier (KM) product limit method was used
to estimate empirical survival probabilities, including overall
survival and progression-free survival. Log-rank test was applied
to compare survival between patient groups. KM curves were
generated. Progression-free survival was determined as the time
from surgery to recurrence, date of last stable scan, or death.
Multivariate Cox proportional hazard model was applied to
include multiple covariates for survival analysis. Hazard ratio




A total of 25 LITT cases were performed for metastatic brain
tumors on 24 patients between September 2010 to April 2016
at Washington University in St. Louis (Table 1). There were 15
males and 9 females with an average age of 59 years (range 38–
74). Tumor types ranged from primary origin of lung (n = 16),
melanoma (n = 3), followed by breast, colon, ovarian, and
unknown primary. The majority of the lesions were frontal
(n= 11) followed by parietal (n= 8) and other locations (n= 6)
(Table 1). The mean follow-up period was 16.05 months (range
0.7–46.73).
Indications and Operative Details
LITT was chosen as the first-line therapy in only two cases for
which “difficult to resect” location was the primary indication.
For the rest of the cases (n= 23), it was chosen as a secondary or
salvage therapy. In this latter group, surgeons indicated location
as the primary reason for LITT in five of the cases, failure of prior
treatments as the primary reason in 13 cases, and old age as well
as poor functional status in the remaining 5 cases. Six patients
had craniotomy and radiation therapy performed prior to LITT.
Four patients had previous craniotomy and SRS/Gamma knife.
Six patients had prior SRS and no craniotomies.
The average lesion volume was 7.32 cm3 (range 1.00–24.59).
Treatment areas were monitored via standard thermal dose
threshold (TDT) lines, with yellow line signifying the thermal
dose equivalent of 43◦C for 2min and the blue line 43◦C for
10min. TDT lines were not available for two of the cases. Of
the remaining 23 cases, 12 (53%) and 6 (26%) achieved complete
coverage of the contrast-enhancing lesion by the yellow and blue
TDT lines, respectively, with average coverage in the overall
cohort of 95% and 92% by the yellow and blue TDT lines.
Complete coverage of the lesions was limited by ablation area
encroaching on eloquent regions, presence of heat sinks, such as
ventricles or blood vessels near the ablation area, or prohibitively
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Average age, years 59 (38–74)

















Basal Ganglia 1 (4)
Cerebellar 1 (4)
Total 25
There were 24 patients who underwent 25 cases.
large size of the lesions. In 5 (21%) cases, two trajectories were
used to ablate tumor. Postoperative MRI was performed on
postoperative day 1 for evaluation of the extent of ablation and
establishment of a baseline.
Time of surgery was comparable to craniotomy with an
average of 219min (range 105–490). Although not statistically
significant, there was a downward trend over time in operative
time (R2 = 0.21, data not shown). There was no correlation
between surgery time and tumor size or location (data not
shown).
Complications
There was one (4%) perioperative complication and 4 (16%)
later complications leading to unplanned readmissions within
30 days (Table 2). The perioperative complication was a seizure
that occurred in a patient with a large tumor (10.09 cm3). He
was given a dose of 2mg Ativan and 200mg of Vimpat which
abated the seizures and was discharged in stable condition to
rehab on POD 6 on Keppra and Vimpat. One of the re-admission
cases was also potentially due to seizures with presentation of
altered mental status on POD 16. After treatment, this patient
and family opted for comfort care. Two of the readmissions were
due to edema, one of which was secondary to hyponatremia
and responded well to correction of the sodium and the other,
transient hemiparesis, which resolved with a course of steroids.
Analysis of the patients who suffered a complication/readmission
showed that cases with complications were associated with
tumors with larger volume (mean volume 12.32 cm3 ± 7.4)
compared to those who had no complications (mean volume 5.93
cm3 ± 4.96) (unpaired t-test, p= 0.032).
Outcome Data
Of the 25 metastatic brain tumor cases treated with LITT, tumor
volumetric and blue TDT line coverage data were available
on 23 patients. Eight of the cases (32%), either had biopsy
performed at the time of LITT to confirm the diagnosis of
metastasis or did not have prior SRS or RT. Zero patients were
lost to follow-up. At the time of analysis, five (21%) patients
were still alive, with a mean follow-up of 32.26 months (range
7.20–46.73). Among the 19 expired patients, we can identify
systemic disease burden as the cause of death in four patients
and CNS disease as cause of death in six patients whereas specific
cause of death cannot be determined in the remaining nine
patients. The median overall survival (OS) was 13.27 months
[95% confidence interval (CI) = 9.83–23.20] (Figure 1A). The
median progression-free survival (PFS) was 6.30 months (95%
CI = 5.3–17.43) (Figure 1B). Stratified by location, frontal (8 of
24), parietal (5 of 24) or other (6 of 24), did not make a significant
difference on OS (p= 0.429) or PFS (p= 0.364).
To determine if pre-operative tumor size plays a role
in outcome after LITT, pre-procedural tumor volumes were
dichotomized with a cut-off at the median volume of 5.62
cm3. PFS of patients with tumor volumes greater than 5.62
cm3 was significantly shorter than that of patients with tumors
smaller than or equal to 5.62 cm3 [p = 0.024, HR 2.89
(1.12–7.49)] (Figure 2B). However, analysis of OS between
the same two groups did not show a significant difference
[p = 0.164, HR 1.89 (0.76–4.69)] (Figure 2A). To determine
if treatment coverage area based on the blue TDT line has
an effect on outcomes, patients were dichotomized into two
groups based on a treatment coverage cut-off at the median
of 97%. PFS in cases with treatment coverage greater than
97% was significantly longer than those with less than or equal
to 97% blue TDT coverage [p = 0.029, HR 0.36 (0.14–0.93)]
(Figure 3B). OS of cases similarly dichotomized based on a
97% coverage area was not significantly different [p = 0.052,
HR 0.4 (0.16–1.04)] (Figure 3A). Although dataset numbers are
limited, an exploratory multivariate logistic regression analysis
was performed to identify independent predictors of patient
survival outcome. Four variants were included in the model—
age, sex (M vs. F), percentage of blue TDT line coverage
area (>0.97 vs. ≤0.97), and tumor volume (>5.62 vs. ≤5.62).
Multivariate analysis did not show any significant association
between any of the tested parameters and PFS or OS.
DISCUSSION
Our retrospective case series demonstrated that the PFS of
patients with metastatic brain tumors treated with LITT is
improved when greater than 97% of the tumor is treated to
the blue TDT line (Figure 3). The OS of this group trended
to significance (p = 0.052). This is consistent with similar
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TABLE 2 | Complication table.
Patient Pathology Age, years Sex Volume, cm3 Type POD Complication Management
1 L Frontal
Melanoma
60 M 10.09 Perioperative 1 Seizures Antiepileptic
2 R Frontal
Melanoma
56 M 8.91 Readmission 4 Confusion Negative workup. Sent
to rehab on day 2








rehab on day 3
5 R Parietal Lung 65 M 24.59 Readmission 16 AMS, seizures Made comfort care*
One perioperative complication and four readmissions. *Patient 5 came back on post-operative day 16 with altered mental status believed to be secondary to seizures who opted for
comfort care and ultimately expired. POD, post operative day; AMS, altered mental status.
FIGURE 1 | (A) Kaplan-Meier graph of the overall survival (OS) of the
population and the 95% confidence interval (CI). The median OS was 13.27
(95% CI = 9.83–23.20). (B) Shows the progression free survival (PFS) of the
population and the 95% CI. The median PFS was 6.30 (95% CI = 5.3–17.43).
studies describing that extent of surgical resection of metastatic
tumors correlates positively with better outcome (16, 17). Lee
et al. showed that median survival differs significantly when
comparing gross total resection (median survival = 20.4)
to subtotal resection (median survival = 15.1) (p = 0.016).
Our findings suggest that even in cases of irregularly shaped
tumors, use of single or multiple trajectories to achieve greater
than 97% blue TDT treatment coverage, if safe, may be worth
pursuing. A caveat of our study is the possibility that some of
the lesions treated may have represented radiation necrosis. In
our series, 32% of cases either had biopsy done at the time
of LITT to confirm the diagnosis of metastasis or did not
have prior SRS or RT, excluding the possibility of radiation
necrosis at least in these cases. The lack of biopsy-proven
tumor in the remaining cases is noted to be a limitation of
our study. Nevertheless, recent studies have shown that LITT
is also an effective treatment option for radiation necrosis
in medically refractory cases (13, 15). The overall survival
of 13.27 months seen in our group was comparable to that
seen in other studies with surgery and radiation for recurrent
metastatic cases. As another point of comparison, Koiso et al.
retrospectively reviewed 859 patients with metastatic disease who
underwent a second SRS and reported a median survival of 7.4
months (18).
Furthermore, we showed that larger pre-treatment tumor size
is associated with worse outcome, with significantly shorter PFS
and an increase in post-operative complications. However, as
with our extent of TDT coverage data, we did not observe a
clear impact of this factor on OS in patients. This can perhaps
be explained by the fact that overall survival may be dominantly
associated with systemic disease burden rather than central
nervous system disease.
To keep complications at a minimum, patient selection is of
great importance. LITT is ideal for lesions that are deeply seated
and for which open surgery would be difficult, morbid, or at least
transgress some amount of normal brain. However, LITT is also
well-suited for more superficial lesions in patients who are too ill
for surgery, have a thin scalp due to radiation or multiple prior
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FIGURE 2 | (A) Kaplan-Meier graph depicting the OS of patients with the
group dichotomized based on the volume of tumors greater than 5.62 cm3 or
less than and equal to 5.62 cm3. P-value for log rank test and hazard ratio are
depicted on the graph. (B) Kaplan-Meier graph of PFS for patients with tumor
volumes greater than 5.62 cm3 or less than and equal to 5.62 cm3. Log rank
test comparing this two groups shows significantly improved survival for
patients with smaller tumors (p = 0.024).
surgeries, or have tenuous baseline functional status. Ideally, the
target lesion for LITT would be (1) well-circumscribed such that
the lesion could be treated within a 3 cm-diameter cylinder; (2)
average to low vascularity; and (3) accessible via a safe linear
trajectory that avoids inadvertent heating of eloquent structures.
Additionally, the patient and laser apparatus combined must fit
into the bore of the MRI scanner, which can be a limitation
for obese patients. The efficacy of LITT as frontline therapy,
particularly in small tumors, remains to be determined and will
likely require a clinical trial testing the clinical benefit of LITT vs.
SRS with a larger number of patients. But it is the opinion of the
authors that safe supramarginal ablation by LITTmight represent
an interesting alternative to SRS.
With any surgical procedure, operative morbidity and
different treatment options has to be weighed against possible
FIGURE 3 | (A) Kaplan-Meier graph depicting the OS of patients with the
group dichotomized based on the blue thermal dose threshold (TDT) coverage
area of 97%. P-value for log rank test and hazard ratio are depicted on the
graph. (B) Kaplan-Meier graph of PFS for patients with treatment coverage
area greater than 97% or less than and equal to 97%. Log rank test
comparing these two group shows a significantly improved survival for patients
with blue TDT line coverage >97%.
benefits from surgery. In our series we had two cases (8%)
of seizures (Table 2). As a comparison, Gokhale et al. showed
risk of post-operative seizures after craniotomy to be about
7.3% with Keppra treatment (19), which is similar to the
current study. Post-operative edema is another factor that
must be considered with LITT. In our series, two cases
experienced swelling requiring readmission. Post-LITT edema
may potentially be more fulminant than post-craniotomy edema
due to the lack of any decompression with LITT alone. A
prolonged steroid course (2–3 weeks) or a minimally invasive
craniotomy and limited resection immediately following LITT
of larger tumors may represent strategies to mitigate this
phenomenon (20, 21).
The management of incompletely treated tumors by
LITT or recurrent tumors following LITT remains an
open question. In four patients, LITT was repeated for
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recurrent lesions and in three cases the recurring tumors
were treated with SRS. For larger lesions that may be
incompletely ablated, there may be a role for adjuvant SRS
for the residual. There may also be a role for administration
of chemotherapeutic drugs in the post-LITT period given
our prior finding that the BBB is permeable for 4–6 weeks
post-LITT (22).
In summary, LITT is an increasingly attractive treatment
modality for various types of intracranial lesions including brain
metastasis. It offers a minimally invasive option for tumors that
are difficult to access or refractory to prior treatment while at the
same time offering comparable survival outcome to other salvage
therapies.
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